Metsera Reports $116.2M Net Loss, Enters Merger Agreement with Pfizer

Metsera, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company recorded a net loss of $116.2 million for the third quarter, compared to a loss of $109.6 million in the same period last year. For the nine months ended September 30, 2025, the net loss totaled $261.5 million, up from $156.3 million in the prior year. The increase in losses is attributed primarily to heightened research and development expenses, which surged to $181.4 million for the nine-month period, reflecting a $112.8 million increase from the previous year. General and administrative expenses also rose significantly, totaling $35.1 million for the nine months, an increase of $18.1 million year-over-year.

In terms of operational metrics, Metsera's cash and cash equivalents stood at $448.5 million as of September 30, 2025, a notable increase from $352.4 million at the end of 2024. This increase is largely due to the company's initial public offering (IPO) completed in February 2025, which generated net proceeds of approximately $288.4 million. The company has indicated that its available cash is expected to fund operations for at least the next 12 months. However, Metsera continues to face substantial operating losses and anticipates needing additional capital to support ongoing research and development efforts.

Strategically, Metsera has entered into a merger agreement with Pfizer, Inc., which was announced on September 21, 2025. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Metsera for $65.60 per share in cash, plus a contingent value right tied to the achievement of specific milestones. The total equity value of the transaction is approximately $10 billion. Both companies' boards have approved the merger, which is expected to close in the last quarter of 2025, pending regulatory approvals.

The company has also made strides in its product development pipeline. Metsera's lead candidate, MET-097i, has shown promising results in Phase 2b trials, demonstrating a mean placebo-subtracted weight loss of 14.1% after 28 weeks. The company plans to initiate Phase 3 trials for MET-097i by late 2025. Additionally, Metsera's acquisition of Zihipp Ltd. in September 2023 has expanded its pipeline of therapeutics for obesity and diabetes, further enhancing its research capabilities.

Looking ahead, Metsera's management has expressed optimism about the potential of its product candidates, although they acknowledge the inherent risks and uncertainties associated with drug development. The company is focused on advancing its clinical trials and securing necessary regulatory approvals, while also preparing for the operational demands of commercialization. However, the successful completion of the merger with Pfizer and the ability to raise additional capital remain critical to Metsera's future growth and sustainability.